Particle.news
Download on the App Store
3 ARTICLES
·
2mo ago

BioNTech Sues Moderna in Delaware Over Patent Tied to mNEXSPIKE Vaccine

BioNTech says Moderna’s shot uses an optimized mRNA design from Comirnaty that enables lower dosing.

Spritzen mit Impfstoff liegen auf einem Tablett.
Image

Overview

  • BioNTech filed the complaint on Thursday in U.S. federal court in Delaware targeting Moderna’s newly marketed mNEXSPIKE COVID‑19 vaccine.
  • The suit alleges mNEXSPIKE infringes a BioNTech patent covering an optimized mRNA vaccine design employed in Comirnaty that allows lower patient dosing.
  • A Moderna spokesperson told Reuters the company will contest the lawsuit.
  • The U.S. Food and Drug Administration approved Moderna’s next‑generation mNEXSPIKE vaccine in 2025.
  • The filing joins a broader wave of COVID‑19 vaccine patent disputes, with Moderna’s 2022 case against Pfizer and BioNTech still pending and Bayer’s January suit alleging use of a Monsanto stabilization technique; Pfizer is not a party to the new case.